Patients with primary and secondary pulmonary hypertension.

• Integrate cross-department teams to provide comprehensive medical care, and adopt a 24-hour on-call mechanism to deal with critical patient situations as soon as possible.

• Develop strategic alliances and medical partnerships with other hospitals. Provide clinical guidance, teaching, and training for physicians and medical staff. Formulate standardized medical operations. Establish an evacuation and referral system to improve regional medical standards.

• Integrate with international pulmonary hypertension centers, enhance international cooperation, arrange team members visiting and learning in international pulmonary hypertension centers, publish manuscript in international journals.

• Dedicate to the research of pulmonary hypertension, participate in international clinical trials, and dedicate to find unknown fatal mechanisms and treatment directions, with the goal of improving patient survival and quality of life.

• Participation in public welfare activities and help disadvantaged groups. Help patients to regain their confidence and to return to work.

• Educate patients and their families about what is pulmonary hypertension and how to self-care Publish educational books on pulmonary hypertension and provide them free of charge.

Patient-center multidisciplinary care , advance pulmonary hypertension critical care (including ECMO team) and 24-hour continuity back up and care.

• A total of 833 people were served from January 2013 to June 2013

• Pulmonary arterial hypertension (Group 1): 333 people

• Pulmonary hypertension associated with heart disease (Group 2): 137 persons

• Pulmonary hypertension associated with lung diseases (Group 3): 100 persons

• Chronic thromboembolic pulmonary hypertension (Group 4): 43 persons

• Pulmonary hypertension with unclear and/or multifactorial mechanism (Group 5): 220 persons

One of the few medical centers in Taiwan that is equipped with a dedicated pulmonary hypertension nurse in addition to a pulmonary hypertension physician. It provides 24-hour consultation and emergency rescue assistance. The dedicated nurse answers the call at night and activates team members according to the patient's condition. The team not only focuses on caring for patients with primary pulmonary hypertension, but also actively engages in cross-disciplinary team care for patients with secondary pulmonary hypertension. It cooperates with the Rheumatologist to care patients with pulmonary hypertension associated with connective tissue diseases and works with the infection disease specialist to care HIV patients. Pulmonary hypertension group, working with the pediatric cardiologist to treat patients with pulmonary hypertension associated with congenital heart disease. The team also work with the Pulmonologist and cardiacvascular surgeon to care patients with pulmonary hypertension associated with lung disease and heart disease. The one-year survival rate of patients with primary pulmonary hypertension in our hospital is 96.4%, the three-year survival rate is 92.1%, and the five-year survival rate is 86%, all comparable to Japan and South Korea.

• Complete Rate of Oral Medication Guidance: Standardized clinical guidance procedures, shared via in-service education and specific guidance manuals. With individual interventions by case managers and pharmacists for difficult cases, the completion rate of oral medication guidance has reached 100% and is continuously maintained.

• Accuracy Rate of Home Self-Injection: Developed educational video CDs played during hospitalization, coupled with individualized nursing guidance and rigorous assessments. Upon discharge, patients are provided with these videos, emergency cards, and an APP emergency positioning system. Following these interventions, the accuracy rate of home self-injection among patients has increased to 100%.

Our multidisciplinary pulmonary hypertension team delivers comprehensive, continuous care in a professional, empathetic, and reassuring medical environment, empowering patients and families to face the disease with a positive attitude. The team has received numerous letters of gratitude from patients and families expressing deep appreciation, achieving an outstanding overall patient satisfaction rate of 99.8%.

• Invited to serve as moderator and speaker at global pulmonary hypertension conferences such as the International Society of Heart and Lung Transplantation and Pulmonary Vascular Research Institute. Also invited to prepare pulmonary hypertension-related topics for the International Society of Heart and Lung Transplantation’s global annual conference. Write relevant chapters of the pulmonary hypertension textbook.

• Dr. Chih-Hsin Hsu, the leader of the pulmonary hypertension team, was recommended by Professor Vachieny, the former European Chairman of Pulmonary Hypertension, as Fellow of the ESC.

• The team was invited to participate in multiple global clinical trials, and the results were published in high-impact factor journals such as the American Journal of Respiratory and Critical Care Medicine and The Lancet Respiratory Medicine. The team successfully found potential new therapeutic drugs for patients.

• Team members published “Factors associated with health-related quality of life in patients with precapillary pulmonary hypertension: Relationship with nocturnal oxygen desaturation and sleep quality,” in Australia